Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
International Journal of Molecular Sciences · 06.07.2023 · 24 (13) · 11142
DOI: 10.3390/ijms241311142 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.07.2023. Verfasst von Shaul Schreiber und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel. Hauptthemen laut MEDLINE: Analgesics, Opioid, Trazodone. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases, Ari and Regine Aprijaskis Fund, Sylvan Adams Sports Institute.
Themen: Depression
Abstract (Originalsprache)
About 30% of major depression disorder patients fail to achieve remission, hence being diagnosed with treatment-resistant major depression (TRD). Opium had been largely used effectively to treat depression for centuries, but when other medications were introduced, its use was discounted due to addiction and other hazards. In a series of previous studies, we evaluated the antinociceptive effects of eight antidepressant medications and their interaction with the opioid system. Mice were tested with a hotplate or tail-flick after being injected with different doses of mianserin, mirtazapine, trazodone, venlafaxine, reboxetine, moclobemide, fluoxetine, or fluvoxamine to determine the effect of each drug in eliciting antinociception. When naloxone inhibited the antinociceptive effect, we further examined the effect of the specific opioid antagonists of each antidepressant drug. Mianserin and mirtazapine (separately) induced dose-dependent antinociception, each one yielding a biphasic dose-response curve, and they were antagonized by naloxone. Trazodone and venlafaxine (separately) induced a dose-dependent antinociceptive effect, antagonized by naloxone. Reboxetine induced a weak antinociceptive effect with no significant opioid involvement, while moclobemide, fluoxetine, and fluvoxamine had no opioid-involved antinociceptive effects. Controlled clinical studies are needed to establish the efficacy of the augmentation of opiate antidepressants in persons with treatment-resistant depression and the optimal dosage of drugs prescribed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
- Dr. Miriam and Sheldon G. Adelson Clinic for Drug Abuse Treatment and Research, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
- Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel.
- Sylvan Adams Sports Institute, Tel Aviv University, Tel Aviv 6905904, Israel.
- Department of Anatomy and Anthropology, Tel Aviv University, Tel Aviv 6905904, Israel.
- Dr. Miriam and Sheldon G. Adelson Chair and Center for the Biology of Addictive Diseases, Tel Aviv University, Tel Aviv 6905904, Israel.
ORCID-Profile: Chaim G Pick
Förderung
- Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases
- Ari and Regine Aprijaskis Fund
- Sylvan Adams Sports Institute
- Dr. Miriam and Sheldon G. Adelson Center
Zitieren
APA
Schreiber, S., Keidan, L., & Pick, C. G. (2023). Treatment-Resistant Depression (TRD): Is the Opioid System Involved?. International Journal of Molecular Sciences, 24(13), 11142. https://doi.org/10.3390/ijms241311142
Vancouver
Schreiber S, Keidan L, Pick CG. Treatment-Resistant Depression (TRD): Is the Opioid System Involved?. International Journal of Molecular Sciences. 2023;24(13):11142. doi:10.3390/ijms241311142
BibTeX
@article{Schreiber2023,
author = {Schreiber, Shaul and Keidan, Lee and Pick, Chaim G},
title = {Treatment-Resistant Depression (TRD): Is the Opioid System Involved?},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {13},
pages = {11142},
doi = {10.3390/ijms241311142}
}
EUVIMED